# The Use of ARA290 for the Treatment of Diabetic Macular Oedema

> **NCT06626971** · PHASE2 · TERMINATED · sponsor: **Belfast Health and Social Care Trust** · enrollment: 9 (actual)

## Conditions studied

- Diabetic Macular Oedema

## Interventions

- **DRUG:** ARA290

## Key facts

- **NCT ID:** NCT06626971
- **Lead sponsor:** Belfast Health and Social Care Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-04
- **Primary completion:** 2017-05-12
- **Final completion:** 2017-08
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Expiry of study drug - no replacement available.
- **Last updated:** 2024-10-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06626971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06626971, "The Use of ARA290 for the Treatment of Diabetic Macular Oedema". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06626971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*